Loading…
Inovio Pharmaceuticals, Inc. is projected to rise to $1.52 by 2027, a +21% move from its current price of $1.25. INO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.20 | $1.25 | $1.30 | -0.02% |
| May 30 | $1.19 | $1.25 | $1.32 | -0.04% |
| May 31 | $1.17 | $1.25 | $1.33 | -0.06% |
| Jun 1 | $1.16 | $1.25 | $1.35 | -0.08% |
| Jun 2 | $1.15 | $1.25 | $1.36 | -0.10% |
| Jun 3 | $1.14 | $1.25 | $1.37 | -0.12% |
| Jun 4 | $1.13 | $1.25 | $1.38 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.13 | $1.25 | $1.38 | -0.14% |
| Week 2 | $1.08 | $1.25 | $1.43 | -0.29% |
| Week 3 | $1.05 | $1.24 | $1.48 | -0.43% |
| Week 4 | $1.02 | $1.24 | $1.51 | -0.58% |
| Week 5 | $0.9962 | $1.24 | $1.55 | -0.72% |
| Week 6 | $0.9741 | $1.24 | $1.58 | -0.86% |
| Week 7 | $0.9541 | $1.24 | $1.60 | -1.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial.
Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals, Inc. (INO) is a biotechnology company categorized in Healthcare. The current price is $1.25, and the market capitalization is $102.84M, with a market rank of 4169.
The stock trades in a 30-day range from $0.9785 to $1.60, with a support level at $1.10 and a resistance at $1.46. The near-term technical picture shows neutral sentiment with a 14-day RSI of 50, a SMA50 of $1.31, and a SMA200 of $1.85. Annualized volatility is around 70%.
The forecast implies a bullish long-term trajectory, with year-by-year price expectations that trend higher from 2026 onward, including an average price of $1.25 in 2026 rising to multi-year highs later in the horizon.
A major floor 27.2% below — a decisive break under it would weaken the trend.
The nearest floor, 12.0% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 51.2% above — clearing it would confirm fresh momentum.
Key INO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.28 | Sell | $1.28 | Sell |
| MA 10 | $1.29 | Sell | $1.28 | Sell |
| MA 20 | $1.27 | Sell | $1.28 | Sell |
| MA 50 | $1.31 | Sell | $1.34 | Sell |
| MA 100 | $1.48 | Sell | $1.49 | Sell |
| MA 200 | $1.85 | Sell | $1.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.36 | Neutral |
| Stoch RSI (14) | 11.64 | Buy |
| CCI (20) | -14.06 | Neutral |
| Williams %R (14) | -87.50 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -14.38 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 12.50 | Buy |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 46.19 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 1.30 | Sell |
| ADX (14) | 15.90 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is neutral. RSI(14) stands at 50, indicating balanced momentum around the midpoint. The 50-day moving average sits at $1.31, while the 200-day moving average is $1.85, suggesting recent weakness relative to longer-term trends.
The asset trades between a $1.10 support and a $1.46 resistance, consistent with a tight range around the current price. The 30-day range spans from $0.9785 to $1.60, signaling limited volatility over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.05 | $1.25 | $1.64 | 0% | Neutral | |
| $1.16 | $1.52 | $2.12 | +21% | Bullish | |
| $1.41 | $1.92 | $2.81 | +53% | Bullish | |
| $1.39 | $1.95 | $2.96 | +56% | Bullish | |
| $1.50 | $2.17 | $3.39 | +73% | Bullish | |
| $1.50 | $2.22 | $3.57 | +77% | Bullish | |
| $1.34 | $2.04 | $3.35 | +63% | Bullish | |
| $1.42 | $2.22 | $3.73 | +77% | Bullish | |
| $1.63 | $2.59 | $4.45 | +107% | Bullish | |
| $1.94 | $3.16 | $5.51 | +153% | Bullish | |
| $1.94 | $3.50 | $6.60 | +180% | Bullish | |
| $3.74 | $8.15 | $17.10 | +552% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.05 | $1.25 | $1.46 | +0.00% |
| June 2026 | $1.02 | $1.20 | $1.46 | -3.85% |
| July 2026 | $1.02 | $1.23 | $1.52 | +2.06% |
| August 2026 | $0.9899 | $1.20 | $1.50 | -2.49% |
| September 2026 | $0.9393 | $1.14 | $1.45 | -4.40% |
| October 2026 | $0.9706 | $1.19 | $1.53 | +4.05% |
| November 2026 | $1.02 | $1.26 | $1.63 | +5.99% |
| December 2026 | $1.01 | $1.25 | $1.64 | -0.54% |
Click any year to see its month-by-month INO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INO price prediction for 2026 points to an average of $1.25 (low $1.05, high $1.64) — a potential gain of 0% on today's $1.25. A consolidation phase looks the most probable path here.
In 2027, INO is projected to trade between $1.16 and $2.12, averaging $1.52 — a potential gain of +21% from today's $1.25. That is up +21% on the projected 2026 average. Momentum favours further upside here.
Inovio Pharmaceuticals, Inc.'s 2028 outlook centres on $1.92, within a $1.41 to $2.81 range. That is up +27% on the projected 2027 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, INO could reach as high as $2.96, with a base case around $1.95 and support toward $1.39 — roughly +56% from $1.25. Momentum favours further upside here.
Expect INO to range from $1.50 to $3.39 through 2030. The $2.17 average target implies a +73% move from current prices. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The INO price prediction for 2031 points to an average of $2.22 (low $1.50, high $3.57) — a potential gain of +77% on today's $1.25. Momentum favours further upside here.
In 2032, INO is projected to trade between $1.34 and $3.35, averaging $2.04 — a potential gain of +63% from today's $1.25. That is -8% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Inovio Pharmaceuticals, Inc.'s 2033 outlook centres on $2.22, within a $1.42 to $3.73 range. That is up +9% on the projected 2032 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2034, INO could reach as high as $4.45, with a base case around $2.59 and support toward $1.63 — roughly +107% from $1.25. Buyers look set to stay in control over this stretch.
Expect INO to range from $1.94 to $5.51 through 2035. The $3.16 average target implies a +153% move from current prices. That is up +22% on the projected 2034 average. Momentum favours further upside here.
The INO price prediction for 2040 points to an average of $3.50 (low $1.94, high $6.60) — a potential gain of +180% on today's $1.25. Buyers look set to stay in control over this stretch.
In 2050, INO is projected to trade between $3.74 and $17.10, averaging $8.15 — a potential gain of +552% from today's $1.25. That is up +133% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INO today (≈ 800 INO) could be worth
$6,517.75
+$5,517.75 (+552%) by 2050 · US Dollar
Based on the average projected INO price of $8.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INOwould be worth at today's price.
$1,000 invested in INO on May 27, 2025 (≈ 500 INO) would be worth
$625
-$375 (-37.5%) today · 0.63× · US Dollar
Based on a INO entry price of $2 vs. today's $1.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.23 | $1,016.26 | +1.6% |
| 1 month ago | $1.17 | $1,068.38 | +6.8% |
| 3 months ago | $1.79 | $698.32 | -30.2% |
| 6 months ago | $2.06 | $606.8 | -39.3% |
| 1 year ago | $2 | $625 | -37.5% |
| All time (5.0y) ago | $89.28 | $14 | -98.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INO forecast.
Our base-case forecast reaches $2.50 around 2034.
Implied market cap at $2.50: $205.68M
The multi-year forecast shows a clear bullish tilt after 2026, with the average price rising from $1.25 in 2026 to $2.17 by 2030 and then higher through 2035 and beyond. Notably, the 2034 average is $2.59 and the 2035 average is $3.16, with corresponding max values of $4.45 and $5.51, respectively. By 2040, the average is projected at $3.50 and by 2050 at $8.15, with a 2050 max of $17.10.
Cumulative upside is reflected in ROI percentages, reaching 73.3% in 2030, 152.5% in 2035, 180.3% in 2040, and a peak of 551.8% in 2050. The outlook remains bullish but these are estimates, not guarantees, and depend on market factors and company development milestones. Ensure consideration of risk and volatility inherent in small-cap biotech equities.
Tap a question to reveal the answer.
2030 avg $2.17; min $1.50; max $3.39; ROI 73.3%.
The forecast shows a bullish path starting in 2027 with avg prices rising to $2.22 by 2031 and up to $8.15 on average by 2050, with a max of $17.10 and ROI of 551.8% in 2050. These are projections, not guarantees, and should be weighed against risks.
Yes, the forecast indicates a 2035 max of $5.51, with earlier years showing lower maxes (e.g., 2034 max $4.45). The long-term upside also includes a 2050 max of $17.10, but these remain estimates.
2026 avg $1.25; min $1.05; max $1.64; ROI 0%.
Current price is $1.25 and market cap is $102.84M.
Inovio Pharmaceuticals, Inc. Community Discussion
0Share your Inovio Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.